or Try an Advanced Search...

    Technical Analysis for KALA - Kala Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 6.89 -2.82% -0.20
    KALA closed down 2.82 percent on Monday, July 1, 2024, on 1.18 times normal volume. It was able to find support at its 50 day moving average. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical KALA trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    50 DMA Support Bullish 0.00%
    Calm After Storm Range Contraction 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    200 DMA Resistance Bearish -2.82%
    MACD Bullish Signal Line Cross Bullish -2.82%
    Pocket Pivot Bullish Swing Setup -2.82%
    Volume Surge Other -2.82%
    Older End-of-Day Signals for KALA ...

       Recent Intraday Alerts

    Alert Time
    Fell Below 50 DMA about 9 hours ago
    50 DMA Support about 10 hours ago
    Fell Below Previous Day's Low about 10 hours ago
    Down 10% about 10 hours ago
    Down 1 ATR about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    KALA Chart by TradingView
    Basic chart:

    Profile

    Kala Pharmaceuticals Inc. is a United States-based company that is developing ophthalmic treatments based on the Company’s Mucosal Penetrating Product (MPP) platform. The Company’s topical ocular MPP formulations enhance penetration of diverse therapeutic agents into ocular tissue, including those in the back of the eye, by facilitating penetration through the mucus layer of tear film. Its product development pipeline includes a 1% formulation of loteprednol etabonate to treat post-surgical ocular inflammation and pain; a 0.25% LE-MPP formulation for dry eye, blepharitis, and retinal disease, and a topically applied receptor tyrosine kinase inhibitir (RTKi-MPP) for the treatment of wet age-related macular degeneration (AMD).
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Organ Systems Pain Eye Inflammation Ophthalmic Macular Degeneration Tyrosine Kinase Retina Wet Age Related Macular Degeneration Glucocorticoids Receptor Tyrosine Kinase Retinal Disease Blepharitis Post Surgical Ocular Inflammation

    Is KALA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 27 Kala Pharmaceuticals to sell 1.197M shares at $5.85 in private placement
    Jun 27 KALA BIO Announces $12,500,000 Private Placement
    May 29 KALA BIO to Present at Jefferies Global Healthcare Conference
    May 21 Wall Street Analysts Just Trimmed Price Target for KALA BIO, Inc. (NASDAQ:KALA)
    May 14 Kala Pharmaceuticals GAAP EPS of -$4.20
    May 14 KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
    Mar 29 Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44
    Mar 29 KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    Feb 26 KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
    Feb 6 KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
    See more KALA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.11
    52 Week Low 4.21
    Average Volume 281,436
    200-Day Moving Average 7.21
    50-Day Moving Average 6.40
    20-Day Moving Average 6.02
    10-Day Moving Average 5.64
    Average True Range 0.63
    RSI (14) 59.84
    ADX 23.32
    +DI 34.43
    -DI 20.82
    Chandelier Exit (Long, 3 ATRs) 5.71
    Chandelier Exit (Short, 3 ATRs) 6.10
    Upper Bollinger Bands 7.51
    Lower Bollinger Band 4.53
    Percent B (%b) 0.79
    BandWidth 49.49
    MACD Line -0.12
    MACD Signal Line -0.28
    MACD Histogram 0.1589
    Fundamentals Value
    Market Cap 18.56 Million
    Num Shares 2.69 Million
    EPS -22.38
    Price-to-Earnings (P/E) Ratio -0.31
    Price-to-Sales 1.16
    Price-to-Book 1.77
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 8.36
    Resistance 3 (R3) 8.33 7.82 8.12
    Resistance 2 (R2) 7.82 7.44 7.83 8.03
    Resistance 1 (R1) 7.35 7.21 7.10 7.38 7.95
    Pivot Point 6.84 6.84 6.71 6.85 6.84
    Support 1 (S1) 6.37 6.46 6.12 6.40 5.83
    Support 2 (S2) 5.86 6.23 5.87 5.75
    Support 3 (S3) 5.39 5.86 5.67
    Support 4 (S4) 5.42